Lesion-targeted injectable vectors for vascular restenosis

Human Gene Therapy

Volumn 12, Issue 10, 2001, Pages 1277-1287

  Gordon, E M ^a   Nian Ling Zhu, ^a   Prescott, M F ^b   Zhen Hai Chen, ^a   Anderson, W F ^a   Hall, F L ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE CYCLIN G1 PROTEIN; COLLAGEN; PROTEIN; SCLEROPROTEIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR; VON WILLEBRAND FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CATHETERIZATION; ARTERY INJURY; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INSTILLATION; ENDOTHELIUM INJURY; EXTRACELLULAR MATRIX; GENE TARGETING; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; INTIMA; MOUSE; NONHUMAN; RAT; RESTENOSIS;

3T3 CELLS; ANGIOPLASTY, BALLOON; ANIMALS; BETA-GALACTOSIDASE; BLOTTING, WESTERN; CAROTID ARTERY INJURIES; CELL LINE; COLLAGEN; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; MICE; PROTEIN STRUCTURE, TERTIARY; RATS; RATS, WISTAR; RETROVIRIDAE; TIME FACTORS; TRANSDUCTION, GENETIC;

ANIMALIA; NEXUS; RNA VIRUSES;

EID: 0034924767     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303401750270931     Document Type: Article

References (47)

1. Suppression of neointimal smooth muscle cell accumulation in vivo by antisense CDC2 and CDK2 oligonucleotides in rat carotid artery
2. Human gene therapy
3. Control of vascular smooth muscle cell growth and its implication in atherosclerosis and restenosis
4. Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types
5. Cell cycle progression: New therapeutic target for vascular proliferative disease
6. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells
7. Mechanisms of restenosis
8. Adenovirus-meditated over-expression of the cyclin/cyclin dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty
9. Adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene inhibits vascular smooth muscle cell proliferation and neointima formation following balloon angioplasty of the rat carotid artery
10. Retroviral vector-mediated transfer of an antisense cyclin G1 construct inhibits osteosarcoma tumor growth in nude mice
11. Retroviral targeting by envelopes expressing an N-terminal binding domain
12. Mechanisms of neointima formation-lessons from experimental models
13. Fusigenic liposome-mediated DNA transfer into cardiac myocytes
14. Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct
15. Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice
16. Targeting retro-viral vectors to vascular lesions by genetic engineering of the Mo-MuLV gp70 envelope protein
17. Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor
18. Intratumoral injection of a concentrated antisense cyclin G1 retroviral vector inhibits growth of undifferentiated carcinoma in nude mice
19. Clinical protocol: Arterial gene therapy for restenosis
20. Inhibition of rabbit keratocyte and human fetal lens epithelial cell proliferation by retroviral-mediated transfer of antisense cyclin G1 and antisense MAT1 constructs
21. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions
22. Gene transfer into the carotid artery using an adventitial collar: Comparison of the effectiveness of the plasmid-liposome complexes, retroviruses, pseudotyped retroviruses, and adenoviruses; plasmid-liposome complex, retrovirus vector and adenovirus vector-mediated beta-galactosidase reporter gene transfer for vascular disease therapy
23. Retroviral vector targeting to melanoma cells by single-chain antibody incorporation in envelope
24. Cellular mechanisms involved in the vascular myogenic response
25. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection
26. Analysis of the functional and host range-determining regions of the murine ecotropic and amphotropic retrovirus envelope proteins
27. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo
28. Targeting of retroviral vectors through protease-substrate interactions
29. Viral vector targeting
30. A gene delivery system activatable by disease-associated matrix metalloproteinases
31. Development of amphotropic retrovirus vectors resistant to inactivation by human serum
32. Targeting of retroviral vectors for gene therapy
33. The restenosis paradigm revisited: An alternative proposal for cellular mechanisms
34. Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo
35. Retroviral vector-mediated gene transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic sarcoma cells
36. A transient three-plasmid expression system for the production of high titer retroviral vectors
37. A collagen/gelatin-binding decapeptide derived from bovine propolypeptide of von Willebrand factor
38. Cyclin G: A new mammalian cyclin with homology to fission yeast Cig1
39. Characterization of the proline-rich region of murine leukemia virus envelope protein
40. Characterization of differential gene expression in monkey arterial neointima following balloon catheter injury
41. Molecular cloning of the human CYCG1 gene encoding a G-type cyclin: Overexpression in osteosarcoma cells
42. Long term inhibition of neointima formation in balloon-injured rat arteries by intraluminal instillation of a matrix-targeted retroviral vector bearing a cytocidal mutant cyclin G1 construct
43. Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle
44. Generation of retroviral vector for clinical studies using transient transfection
45. Identification of the block in targeted retroviral-mediated gene transfer
46. Down-regulation of cyclin G1 expression by retrovirus-mediated antisense gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation
47. Mutational analysis of the fusion peptide of Moloney murine leukemia virus transmembrane protein p15E